PEOPLE - Ceapro makes appointment:
This article was originally published in Clinica
Edmonton, Alberta-based Ceapro has appointed Oleh Hnatiuk as acting managing director of its Ceapro Technology subsidiary. He will have supervision of the commercial activities relating to AccuScreen, the group's type 2 diabetes early detection test. Mr Hnatiuk is president of technology commercialisation advisory company Connect Capital Corp and was formerly president of University Technologies International. His skills and experience in networking will be employed at a critical time for the commercial introduction of AccuScreen, said Ceapro president and CEO Dr Mark Redmond.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.